Menlo Therapeutics to Present at Upcoming Investor Conferences
May 31 2018 - 5:00PM
Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage
biopharmaceutical company focused on the development of serlopitant
for the treatment of pruritus associated with various underlying
dermatologic conditions and for refractory chronic cough, today
announced that management will participate in the following
upcoming investor conferences:
- Jefferies 2018 Healthcare Conference on Thursday, June 7, 2018
at 4:00 p.m. ET in New York, New York
- Cantor Fitzgerald Dermatology and Aesthetics Summit on Tuesday,
June 19, 2018 at 1:00 p.m. ET in New York, New York
- JMP Securities 2018 Life Science Conference on Wednesday, June
20, 2018 at 10:00 a.m. ET in New York, New York
The Jefferies and JMP conference presentations will be webcast
live and can be accessed by logging onto the “Investors” section of
the Menlo Therapeutics website, www.menlotherapeutics.com, prior to
the event. Replays of the webcasts will be archived on the
Company’s website for 30 days following the presentation.
About Menlo Therapeutics
Menlo Therapeutics Inc. is a late-stage biopharmaceutical
company focused on the development of serlopitant, a once-daily
oral NK1 receptor antagonist, for the treatment of pruritus
associated with various underlying dermatologic conditions and for
refractory chronic cough. The Company’s clinical development
program for serlopitant includes ongoing Phase 2 studies for the
treatment of pruritus associated with psoriasis and refractory
chronic cough and ongoing and planned Phase 3 studies for the
treatment of pruritus associated with prurigo nodularis.
Media Contact: media@menlotx.com
Investor Contact: dsheel@menlotx.com
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Apr 2023 to Apr 2024